NALTREXONE

Low dose naltrexone, LDN, has a large body of pre-clinical evidence that speak to possible benefits.

There are some fascinating case studies including one from 2010 in advanced kidney cancer where continuous therapy together with intravenous vitamin C is reported to have stabilized and reduce disease activity over multiple years. In pilot trials for breast cancer the activity has been reported to be insufficient to warrent extending the research. Additionally there are a few case studies in prostate cancer, used with a vaccine based immunotherapy regime. Research is continuing, including for melanoma, prostate and kidney cancers.

Its possible low dose naltrexone will find uses to improve results in oncology including immunotherapy. LDN should only be considered together with your oncologist.

Out of 13 patients we enrolled, 8 patients had serial PET-CT scans that were evaluable for response. Of these 8 patients, 5 had stable or decreased SUVmax values at 4 weeks and 3 had clinical or imaging progression. Median time to progression was short at 7 weeks. Naltrexone was well tolerated. There were no discontinuations due to toxicity and no grade 3 or 4 toxicities were noted. Naltrexone showed modest activity in this short study suggesting the contribution of opioid receptors in ER-positive breast cancer. Our data do not support further de...

Particularly promising seems to be the sensitizing action of resistant cancer cells to the applied treatment, as such a strategy will allow not only for more effective pharmacotherapy but also for the use of lower doses of cytotoxic drugs, which in turn translates into a reduction of severe adverse effects of chemotherapy. However, this evidence is still too limited. Hence, there is a necessity to conduct more studies, especially clinical trials on large patient groups, to confirm the existing hypotheses regarding the positive effects of LDN

Combination therapy quickly led to a reduction in prostate-specific antigen levels, and stabilisation of disease was often achieved as indicated by repeat MRI and PET scans. Few side effects of any kind were observed when using these combination treatments. In conclusion, IMM-101 treatment alongside an anti-inflammatory agent, such as bromelain and/or LDN, may be considered an active and safe drug combination, and is a regimen that should be considered for treating patients with prostate cancer

After only a few treatments of IV α-lipoic acid and IV vitamin C, his symptoms began to improve, and the patient regained his baseline weight. His energy and outlook improved, and he returned to work. The patient had stable disease with disappearance of the signs and symptoms of stage IV RCC, a full 9 years following diagnosis, with a gentle integrative program, which is essentially free of side effects… the ALA/N (α-lipoic acid/low-dose naltrexone) protocol appears to induce tumor reduction/dormancy rather than cure the disease process<...

TABLE OF REFERENCES

Help grow the evidence. JOIN us for online forms or try Feedback and Ideas below.

NALTREXONE

TABLE OF REFERENCES

Help grow the community